How a study gets stopped, and who can stop it

Starting a study is documented, and stopping one mostly is not

A great deal of public writing describes how a trial begins. The application, the waiting period, the review board, the first phase.

Far less describes how one ends early, which is odd, because that is where most of the interesting information lives.

The investigational drug rules set out four distinct mechanisms. A hold imposed by the agency, a termination, a period of inactivity, and a withdrawal by the sponsor.

They belong to different parties and they have different grounds. Only some of them leave anything a reader outside the system could ever see.

What a clinical hold actually is

The definition is one sentence, and it is worth having exactly. A clinical hold is an order issued by the agency to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation.

A hold can reach one study or several, because the order may apply to one or more of the investigations covered by an application.

The effect depends on timing. When a proposed study is placed on hold, subjects may not be given the investigational drug at all.

When an ongoing study is placed on hold, no new subjects may be recruited and placed on the drug. Patients already in the study should be taken off therapy unless the agency specifically permits otherwise in the interest of patient safety.

That exception is a small window into how these decisions are made. The safest course for someone already taking something is not always to stop.

The grounds for a first-phase hold

For a proposed or ongoing first-phase investigation, the rule lists the findings that support a hold, and each one is a separate ground.

Human subjects are or would be exposed to an unreasonable and significant risk of illness or injury.

The clinical investigators named in the application are not qualified by reason of their scientific training and experience to conduct the investigation described.

The investigator brochure is misleading, erroneous, or materially incomplete.

The application does not contain sufficient information to assess the risks to subjects of the proposed studies.

A fifth ground concerns exclusion by reproductive potential. Where a drug treats a life-threatening disease affecting both sexes and people with reproductive potential are excluded because of reproductive or developmental toxicity risk, a hold may follow, subject to three named exceptions.

A later-phase study can be held on any of those grounds, plus one more. The plan or protocol is clearly deficient in design to meet its stated objectives.

The list written for studies that are not controlled

A separate paragraph covers any study not designed to be adequate and well-controlled, and its grounds are unlike the others.

A hold may follow where there is reasonable evidence the study is impeding enrollment in, or otherwise interfering with, a study designed to be adequate and well-controlled.

It may follow where insufficient quantities of the drug exist to adequately conduct both kinds of study at once.

It may follow where the drug has been studied in one or more adequate and well-controlled investigations that strongly suggest lack of effectiveness.

It may follow where another drug under investigation or approved for the same indication, available to the same patients, has demonstrated a better potential benefit and risk balance.

It may follow where the drug has already received marketing approval for the same indication in the same population.

And it may follow where the sponsor of the controlled study is not actively pursuing marketing approval of the investigational drug with due diligence.

A closing note softens the effect. The agency ordinarily intends several of those grounds to apply to additional enrollment rather than to eliminate continued access for people already receiving the drug.

How a hold is imposed and lifted

The rule builds in a conversation first. Where the agency concludes a deficiency may be grounds for a hold, it will attempt to discuss and satisfactorily resolve the matter with the sponsor beforehand.

That attempt is skipped in one situation, and the wording is narrow. Unless patients are exposed to immediate and serious risk.

The order itself can move fast. It may be made by telephone or other means of rapid communication, or in writing, and it identifies the studies affected and briefly explains the basis.

A written explanation follows. As soon as possible, and no more than thirty days after imposition, the division director provides the sponsor a written explanation of the basis for the hold.

Lifting it is a separate act. An investigation may only resume after the agency has notified the sponsor that it may proceed.

Where a sponsor requests removal in writing and submits a complete response, the agency responds in writing within thirty calendar days, either removing or maintaining the hold and stating its reasons.

One sentence closes the obvious gap. Notwithstanding that response time, a sponsor may not proceed until it has been notified that the hold has been lifted.

Disagreement has its own route. The sponsor may request reconsideration under the dispute resolution section, which describes an ombudsman for procedural matters and meetings for scientific ones.

Termination, and the ground that names promotion

Termination is a heavier action and the rule describes it as a procedure rather than an event.

If an application is terminated, the sponsor ends all clinical investigations under it and recalls or otherwise provides for the disposition of all unused supplies of the drug.

It is normally preceded by a proposal to terminate and an opportunity for the sponsor to respond. In general the agency first attempts to resolve differences informally, or through the hold procedure.

The first-phase grounds overlap with the hold grounds and then go further. An unreasonable and significant risk. Insufficient information to assess safety.

Manufacturing methods, facilities and controls inadequate to establish and maintain appropriate standards of identity, strength, quality and purity as needed for subject safety.

Investigations being conducted in a manner substantially different than the protocols submitted.

And a ground that reaches directly into commerce. The drug is being promoted or distributed for commercial purposes not justified by the requirements of the investigation, or permitted by the promotion rule.

The list continues with untrue statements of material fact, and with a failure to investigate and report serious and unexpected adverse experiences. It ends with a failure to submit an accurate annual report, a failure to comply with other requirements, and remaining on inactive status for five years or more.

The response window, and the door that skips it

Where the agency proposes to terminate, it notifies the sponsor in writing and invites correction or explanation within a period of thirty days.

The sponsor may respond in writing or request a conference. If the sponsor does not respond within the allocated time, the application is terminated.

If the response is not accepted, the agency informs the sponsor of the reason and offers a regulatory hearing on whether the application should be terminated. The request for that hearing must be made within ten days.

Then comes the paragraph that overrides the rest. If at any time the agency concludes that continuation presents an immediate and substantial danger to the health of individuals, it terminates immediately by written notice from a center director.

Even that is not final. An application terminated that way is subject to reinstatement on additional submissions that eliminate the danger, and the sponsor is offered a hearing on reinstatement.

The quiet ending: inactive status

The third mechanism is the least dramatic and probably the most common, and it is triggered by nothing happening.

Where no subjects are entered into clinical studies for a period of two years or more, the application may be placed on inactive status.

The same follows where all investigations under it remain on clinical hold for one year or more. The agency may act on the sponsor's request or on its own initiative.

On its own initiative it gives notice first, and the sponsor has thirty days to respond as to why the application should remain active.

The consequences are practical. All investigators are notified, and all stocks of the drug are returned or otherwise disposed of.

Annual reports stop, but the application is still in effect for the purposes of public disclosure of data and information.

Resuming takes a protocol amendment with a plan for the coming year, and then a further thirty days before investigations may restart, unless the agency clears them sooner.

And a long silence has an endpoint. An application that remains on inactive status for five years or more may be terminated.

The sponsor's own two exits

A sponsor does not have to wait to be stopped, and two provisions give it a way out.

At any time a sponsor may withdraw an effective application without prejudice. That phrase is doing real work, because it means the withdrawal itself carries no adverse finding.

On withdrawal, the agency is notified, all clinical investigations end, all current investigators are notified, and all stocks are returned or otherwise disposed of at the sponsor's request.

One sentence separates a quiet withdrawal from an alarming one. If an application is withdrawn because of a safety reason, the sponsor shall promptly inform the agency, all participating investigators and all reviewing review boards, together with the reasons.

The second exit is the duty covered in a companion article. A sponsor that determines its drug presents an unreasonable and significant risk discontinues within five working days and notifies everyone involved.

What any of this looks like from outside

Almost none of it is visible, and that is the practical conclusion for a reader.

A hold, a proposed termination, an inactive status and a withdrawal without prejudice all happen between a sponsor and the agency. None produces a public flag on a trial record.

The registry status field is the sponsor's own entry, updated by the sponsor, and a companion article describes what its values mean and what a stale one indicates.

The scope also has to be restated, because it changes what these grounds are worth. The applicability section opens: "Except as provided in this section, this part applies to all clinical investigations of products". It then names them: those "subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to the licensing provisions of the Public Health Service Act".

These are powers over an application and over the people who hold one. A company that has never filed anything is outside that system, so none of this is a sanction hanging over it.

What the grounds do give a reader is a vocabulary. A study can be stopped because it is unsafe, because it is badly designed, because a better option already exists, or because somebody is promoting the drug.

A page that describes a study as ongoing has, without meaning to, made a claim about none of those things having happened. That is a comparison worth holding in mind.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 312.42 — Clinical holds and requests for modification, including the definition of a clinical hold, the grounds for first-phase, later-phase, expanded access and uncontrolled studies, the discussion of deficiency, the thirty-day written explanation, and the resumption procedure — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
2. 21 CFR 312.44 — Termination, including the grounds for each phase, the commercial promotion and distribution ground, the thirty-day response window, the regulatory hearing, and immediate termination for an immediate and substantial danger to health — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
3. 21 CFR 312.45 — Inactive status, including the two-year and one-year triggers, the notification of investigators, the disposal of stocks, the continued effect for public disclosure, the protocol amendment needed to resume, and the five-year termination limit — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
4. 21 CFR 312.38 — Withdrawal of an IND, permitting withdrawal at any time without prejudice and requiring prompt notification of the agency, all participating investigators and all reviewing boards where the withdrawal is for a safety reason — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
5. 21 CFR 312.56 — Review of ongoing investigations, whose final paragraph requires a sponsor to discontinue an investigation presenting an unreasonable and significant risk no later than five working days after making that determination — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
6. 21 CFR 312.2 — Applicability, whose opening sentence states that except as provided in that section the part applies to all clinical investigations of products subject to the approval provisions of the drug law or the licensing provisions of the public health law — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026